Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Sodium–glucose cotransporter 2 (SGLT2) inhibitors have been shown to exert renoprotective effects regardless of the presence of diabetes. However, the etiology of chronic kidney disease (CKD) in children differs from that in adults. In adults, renoprotective benefits have been reported mainly in cases with significant proteinuria, while pediatric CKD is often caused by congenital kidney disease such as congenital anomalies of the kidney and urinary tract (CAKUT) that present with little or no proteinuria.
We report our experience on the renoprotective effects of SGLT2 inhibitors in pediatric CKD patients with minimal proteinuria.
Six pediatric patients who received SGLT2 inhibitors for more than 18 months were analyzed. The underlying diseases were vesicoureteral reflux (n = 2), renal hypoplasia (n = 2), familial juvenile hyperuricemic nephropathy (n = 1), and Alport syndrome (n = 1). The median age at initiation was 16.0 years.
The annual change in estimated glomerular filtration rate (∆eGFR) during the two years before treatment was compared with that observed after six months of SGLT2 inhibitor therapy.
The mean baseline eGFR was 39.0 mL/min/1.73 m² (range: 21.7–72.6).
The mean ΔeGFR during the two years prior to treatment was −3.37 mL/min/1.73 m²/year (range: −9.66 to −2.18).
During the first six months of therapy, ΔeGFR worsened in five cases; however, from six months onward, the mean ΔeGFR improved to −1.82 mL/min/1.73 m²/year (range: −2.95 to 2.02), with improvement observed in all but one case.
The median rate of change was +66.1 % (range: −24.4 to 192.4 %), and three patients demonstrated an upward trend in eGFR.
Adverse events included one case of urinary tract infection and mild hypoglycemic symptoms in two cases.
The five patients showing ΔeGFR improvement had non-glomerular congenital renal diseases or CAKUT with negative or mild proteinuria.
Our findings suggest that SGLT2 inhibitors can exert renoprotective effects even in pediatric CKD patients with minimal proteinuria.
Because SGLT2 inhibitors are known to cause an initial transient decline in GFR (“initial dip”) after therapy initiation, ΔeGFR was evaluated from six months onward, beyond this phase, and improvement was observed in five of the six cases.
